Ultraviolet radiation-induced cytokines promote mast cell accumulation and matrix metalloproteinase production: Potential role in cutaneous lupus erythematosus

Scandinavian Journal of Rheumatology

Volumn 40, Issue 3, 2011, Pages 197-204

  Van Nguyen, H ^a   Di Girolamo, N ^a   Jackson, N ^a   Hampartzoumian, T ^a   Bullpitt, P ^b   Tedla, N ^a   Wakefield, D ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GELATINASE B; INTERLEUKIN 15; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; NEUTRALIZING ANTIBODY; RANTES;

ARTICLE; CELL COUNT; CELL MIGRATION; CLINICAL ARTICLE; DISCOID LUPUS ERYTHEMATOSUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MAST CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; ULTRAVIOLET B RADIATION;

BIOLOGICAL MARKERS; CELL LINE; CELL MOVEMENT; CYTOKINES; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINOCYTES; LUPUS ERYTHEMATOSUS, CUTANEOUS; MAST CELLS; MATRIX METALLOPROTEINASES; SKIN; TISSUE EXTRACTS; ULTRAVIOLET RAYS;

EID: 79955636274     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2010.528020     Document Type: Article

References (50)

1. Werth VP. Clinical manifestations of cutaneous lupus erythematosus. Autoimmun Rev 2005;4:296-302.
2. Crowson AN, Magro C. The cutaneous pathology of lupus erythematosus: a review. J Cutaneous Pathol 2001;28:1-23.
3. Kuhn A, Krammer PH, Kolb-Bachofen V. Pathophysiology of cutaneous lupus erythematosus - novel aspects. Rheumatology (Oxford) 2006;45(Suppl 3):iii14-16.
4. Kuhn A, Sonntag M, Richter-Hintz D, Oslislo C, Megahed M, Ruzicka T, et al. Phototesting in lupus erythematosus: a 15-year experience. J Am Acad Dermatol 2001;45:86-95.
5. Meller S, Winterberg F, Gilliet M, Muller A, Lauceviciute I,Rieker J, et al. Ultraviolet radiation- induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 2005;52:1504-16.
6. Janssens AS, Lashley EE, Out-Luiting CJ, Willemze R, Pavel S, de Gruijl FR. UVB-induced leucocyte trafficking in the epidermis of photosensitive lupus erythematosus patients: normal depletion of Langerhans cells. Exp Dermatol 2005;14:138-42.
7. Robson MG, Walport MJ. Pathogenesis of systemic lupus erythematosus (SLE). Clin Exp Allergy 2001;31:678-85.
8. Kuechle MK, Elkon KB. Shining light on lupus and UV. Arthritis Res Ther 2007;9:101.
9. Kanbe N, Tanaka A, Kanbe M, Itakura A, Kurosawa M, Matsuda H. Human mast cells produce matrix metalloproteinase 9. Eur J Immunol 1999;29:2645-9.
10. Di Girolamo N, Indoh I, Jackson N, Wakefield D, McNeil HP, Yan W, et al. Human mast cell-derived gelatinase B (matrix metalloproteinase- 9) is regulated by inflammatory cytokines: role in cell migration. J Immunol 2006;177:2638-50.
11. Norrby K. Mast cells and angiogenesis. APMIS 2002;110:355-71.
12. Tanaka A, Arai K, Kitamura Y, Matsuda H. Matrix metalloproteinase- 9 production, a newly identified function of mast cell progenitors, is downregulated by c-kit receptor activation. Blood 1999;94:2390-5.
13. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 2006;26:299-307.
14. Jackson NE, Wang HW, Tedla N, McNeil HP, Geczy CL, Collins A, et al. IL-15 induces mast cell migration via a pertussis toxinsensitive receptor. Eur J Immunol 2005;35:2376-85.
15. Mattoli S, Ackerman V, Vittori E, Marini M. Mast cell chemotactic activity of RANTES. Biochem Biophys Res Commun 1995;209:316-21.
16. Kuhn A, Ruzicka T. Classification of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T, editors. Cutaneous lupus erythematosus. Heidelberg: Springer, 2004:53-9.
17. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
18. Mawrin C, Brunn A, Rocken C, Schroder JM. Peripheral neuropathy in systemic lupus erythematosus: pathomorphological features and distribution pattern of matrix metalloproteinases. Acta Neuropathol (Berl) 2003;105:365-72.
19. Macluskey M, Chandrachud LM, Pazouki S, Green M, Chisholm DM, Ogden GR, et al. Apoptosis, proliferation, and angiogenesis in oral tissues. Possible relevance to tumour progression. J Pathol 2000;191:368-75.
20. Onoue S, Kobayashi T, Takemoto Y, Sasaki I, Shinkai H. Induction of matrix metalloproteinase-9 secretion from human keratinocytes in culture by ultraviolet B irradiation. J Dermatol Sci 2003; 33:105-11.
21. Yano S, Komine M, Fujimoto M, Okochi H, Tamaki K. Interleukin 15 induces the signals of epidermal proliferation through ERK and PI 3-kinase in a human epidermal keratinocyte cell line, HaCaT. Biochem Biophys Res Commun 2003;301:841-7.
22. Mohamadzadeh M, Takashima A, Dougherty I, Knop J, Bergstresser PR, Cruz PD Jr. Ultraviolet B radiation up-regulates the expression of IL-15 in human skin. J Immunol 1995;155:4492-6.
23. Benoist C, Mathis D. Mast cells in autoimmune disease. Nature 2002;420:875-8.
24. Fairhurst AM, Wandstrat AE, Wakeland EK. Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv Immunol 2006;92:1-69.
25. Sayed BA, Brown MA. Mast cells as modulators of T-cell responses. Immunol Rev 2007;217:53-64.
26. Lukacs NW, Hogaboam CM, Kunkel SL, Chensue SW, Burdick MD, Evanoff HL, et al. Mast cells produce ENA-78, which can function as a potent neutrophil chemoattractant during allergic airway inflammation. J Leukoc Biol 1998;63:746-51.
27. Shakoory B, Fitzgerald SM, Lee SA, Chi DS, Krishnaswamy G. The role of human mast cell-derived cytokines in eosinophil biology. J Interferon Cytokine Res 2004;24:271-81.
28. Gordon JR. TGFbeta1 and TNFalpha secreted by mast cells stimulated via the FcepsilonRI activate fibroblasts for high-level production of monocyte chemoattractant protein-1 (MCP-1). Cell Immunol 2000;201:42-9.
29. Meyer MC, Creer MH, McHowat J. Potential role for mast cell tryptase in recruitment of inflammatory cells to endothelium. Am J Physiol 2005;289:C1485-91.
30. Yamamoto T, Katayama I, Nishioka K. Mast cell numbers in multiple dermatofibromas. Dermatology 1995;190:9-13.
31. Fagot D, Asselineau D, Bernerd F. Direct role of human dermal fibroblasts and indirect participation of epidermal keratinocytes in MMP-1 production after UV-B irradiation. Arch Dermatol Res 2002;293:576-83.
32. Baba H, Uchiwa H, Watanabe S. UVB irradiation increases the release of SCF from human epidermal cells. J Invest Dermatol 2005;124:1075-7.
33. Kock A, Schwarz T, Kirnbauer R, Urbanski A, Perry P, Ansel JC, et al. Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med 1990;172:1609-14.
34. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002;109:625-37.
35. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-39.
36. Deshmukh US, Gaskin F, Lewis JE, Kannapell CC, Fu SM. Mechanisms of autoantibody diversification to SLE-related autoantigens. Ann N Y Acad Sci 2003;987:91-8.
37. Graham KL, Utz PJ. Sources of autoantigens in systemic lupus erythematosus. Curr Opin Rheumatol 2005;17:513-17.
38. Schwarz T. Mechanisms of UV-induced immunosuppression. Keio J Med 2005;54:165-71.
39. Kuhn A, Herrmann M, Kleber S, Beckmann-Welle M, Fehsel K, Martin-Villalba A, et al. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum 2006;54:939-50.
40. Reefman E, Kuiper H, Jonkman MF, Limburg PC, Kallenberg CG, Bijl M. Skin sensitivity to UVB irradiation in systemic lupus erythematosus is not related to the level of apoptosis induction in keratinocytes. Rheumatology (Oxford) 2006; 45:538-44.
41. Reefman E, de Jong MC, Kuiper H, Jonkman MF, Limburg PC, Kallenberg CG, et al. Is disturbed clearance of apoptotic keratinocytes responsible for UVB-induced inflammatory skin lesions in systemic lupus erythematosus? Arthritis Res Ther 2006; 8:R156.
42. Muller DM, Pender MP, Greer JM. Chemokines and chemokine receptors: potential therapeutic targets in multiple sclerosis. Curr Drug Targets Inflamm Allergy 2004;3:279-90.
43. Rottem M, Mekori YA. Mast cells and autoimmunity. Autoimmun Rev 2005;4:21-7.
44. Eklund KK. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol Rev 2007;217:38-52.
45. Mortier E, Bernard J, Plet A, Jacques Y. Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol 2004;173:1681-8.
46. Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum 2005;52:2686-92.
47. Cawston TE. Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol Ther 1996;70:163-82.
48. Mengshol JA, Mix KS, Brinckerhoff CE. Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull's-eye or missing the mark? Arthritis Rheum 2002;46:13-20.
49. Close DR. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis 2001;60(Suppl 3):iii62-7.
50. Catterall JB, Cawston TE. Drugs in development: bisphosphonates and metalloproteinase inhibitors. Arthritis Res Ther 2003;5:12-24.